[go: up one dir, main page]

MA33293B1 - Procédé d'amélioration du profil de dissolution d'une matière biologiquement active - Google Patents

Procédé d'amélioration du profil de dissolution d'une matière biologiquement active

Info

Publication number
MA33293B1
MA33293B1 MA34379A MA34379A MA33293B1 MA 33293 B1 MA33293 B1 MA 33293B1 MA 34379 A MA34379 A MA 34379A MA 34379 A MA34379 A MA 34379A MA 33293 B1 MA33293 B1 MA 33293B1
Authority
MA
Morocco
Prior art keywords
biologically active
improving
dissolution
active substance
grinding
Prior art date
Application number
MA34379A
Other languages
Arabic (ar)
English (en)
Inventor
Aaron Dodd
Felix Meiser
Adrian Russell
Marck Norret
William H Bosch
Matt Callahan
Original Assignee
Iceutica Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2009901741A external-priority patent/AU2009901741A0/en
Application filed by Iceutica Pty Ltd filed Critical Iceutica Pty Ltd
Publication of MA33293B1 publication Critical patent/MA33293B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
    • A01N25/12—Powders or granules
    • A01N25/14—Powders or granules wettable
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Dentistry (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Disintegrating Or Milling (AREA)

Abstract

La présente invention concerne un procédé d'amélioration du profil de dissolution d'une matière biologiquement active qui comprend les étapes de broyage à sec d'une matière solide biologiquement active et d'une matrice de broyage pouvant être broyée dans un broyeur comprenant des corps de broyage, pendant une durée suffisante pour produire des particules de la matière biologiquement active dispersées dans une matière de broyage au moins partiellement broyée.
MA34379A 2009-04-24 2010-04-23 Procédé d'amélioration du profil de dissolution d'une matière biologiquement active MA33293B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17230109P 2009-04-24 2009-04-24
AU2009901741A AU2009901741A0 (en) 2009-04-24 Method for Improving the Dissolution Profile of a Biologically Active Material
PCT/AU2010/000465 WO2010121321A1 (fr) 2009-04-24 2010-04-23 Procédé d'amélioration du profil de dissolution d'une matière biologiquement active

Publications (1)

Publication Number Publication Date
MA33293B1 true MA33293B1 (fr) 2012-05-02

Family

ID=43010604

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34379A MA33293B1 (fr) 2009-04-24 2010-04-23 Procédé d'amélioration du profil de dissolution d'une matière biologiquement active

Country Status (21)

Country Link
US (6) US20120165323A1 (fr)
EP (1) EP2421516A4 (fr)
JP (3) JP5898613B2 (fr)
KR (3) KR101873500B1 (fr)
CN (3) CN103830243A (fr)
AP (2) AP2015008965A0 (fr)
AU (2) AU2010239160B2 (fr)
BR (1) BRPI1014277A2 (fr)
CA (1) CA2759104C (fr)
CO (1) CO6470804A2 (fr)
EA (1) EA201171280A1 (fr)
IL (1) IL215871B (fr)
MA (1) MA33293B1 (fr)
MX (1) MX360545B (fr)
MY (1) MY163538A (fr)
NZ (1) NZ595972A (fr)
PH (1) PH12015501781A1 (fr)
SG (1) SG175308A1 (fr)
UA (1) UA110772C2 (fr)
WO (1) WO2010121321A1 (fr)
ZA (1) ZA201108647B (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5508003B2 (ja) 2006-06-30 2014-05-28 アイスイティカ ピーティーワイ リミテッド ナノ粒子状の形態における生物学的に活性な化合物の調製のための方法
BRPI1014878A2 (pt) * 2009-04-24 2016-05-03 Iceutica Pty Ltd "produção de nanopartículas encapsuladas em frações de alto volume."
CA2759108C (fr) * 2009-04-24 2020-05-05 Iceutica Pty Ltd Formes de dosage unitaire solide renfermant du celecoxib
BRPI1014275B8 (pt) 2009-04-24 2021-05-25 Iceutica Pty Ltd composição que compreende partículas de indometacina dispersas em pelo menos dois materiais de moagem parcialmente moídos
KR20120104489A (ko) * 2009-04-24 2012-09-21 아이슈티카 피티와이 리미티드 신규의 나프록센 제제
AU2010239160B2 (en) * 2009-04-24 2014-10-02 Iceutica Pty Ltd Method for improving the dissolution profile of a biologically active material
MX360019B (es) * 2009-04-24 2018-10-15 Iceutica Pty Ltd Una formulación novedosa de metaxalona.
WO2014152207A1 (fr) * 2013-03-15 2014-09-25 Mylan Laboratories, Inc. Formulations de granulation par fusion de principes actifs faiblement hydrosolubles
US20150157646A1 (en) 2013-09-27 2015-06-11 Iceutica Inc. Abiraterone Steroid Formulation
CN104644556B (zh) * 2013-11-22 2018-05-22 沈阳药科大学 盐酸依福地平固体粉末及其制备方法
AU2015200340B2 (en) * 2014-02-05 2019-01-24 Upl Limited Combinations
CN106537128B (zh) 2014-06-09 2021-06-18 生物统计股份有限公司 用于测量分析物的低成本测试条和方法
US9526734B2 (en) 2014-06-09 2016-12-27 Iceutica Pty Ltd. Formulation of meloxicam
US11175268B2 (en) 2014-06-09 2021-11-16 Biometry Inc. Mini point of care gas chromatographic test strip and method to measure analytes
CA2988918A1 (fr) * 2015-06-19 2016-12-22 Biotie Therapies, Inc. Formulations de tozadenant a liberation controlee
JP6968062B6 (ja) * 2015-10-23 2021-12-15 ビーエーエスエフ ソシエタス・ヨーロピアBasf Se 発香性物質及び香味物質とビニルラクタムポリマーとの固溶体
CN105385739B (zh) * 2015-12-09 2017-09-29 梁尚文 －种从金边蚂蟥中制取蛋白肽的方法
ES2988367T3 (es) 2016-07-19 2024-11-20 Biometry Inc Métodos y sistemas para medir analitos utilizando tiras de prueba calibrables por lotes
CN107853670A (zh) * 2017-10-30 2018-03-30 潍坊友容实业有限公司 一种盐地碱蓬生物盐提取方法
CN108379238B (zh) * 2018-01-17 2020-07-14 南昌大学 一种储存物理稳定性好的环孢素固体脂质纳米粒及其制备方法
US12059423B2 (en) 2018-05-11 2024-08-13 Nanjing Delova Biotech Co., Ltd. Meloxicam composition, pharmaceutical preparation and preparation method and use thereof
WO2020046559A1 (fr) * 2018-08-31 2020-03-05 Kemin Industries, Inc. Technologie pour phospholipides et lysophospholipides dispersibles dans l'eau
EP3860570A4 (fr) * 2018-10-05 2022-10-12 Ampersand Biopharmaceuticals, Inc. Formulations et procédés d'administration transdermique de cétones
US11197830B2 (en) 2019-02-27 2021-12-14 Aft Pharmaceuticals Limited Pharmaceutical composition containing acetaminophen and ibuprofen
CN113133970A (zh) * 2020-01-17 2021-07-20 美国琛蓝营养制品股份有限公司 一种姜黄素复合物及其制备方法和检测方法
US20230173073A1 (en) * 2020-06-25 2023-06-08 Omya International Ag Co-ground active(s) comprising product comprising surface-reacted calcium carbonate
TR202017034A2 (tr) * 2020-10-26 2021-09-21 Hacettepe Ueniversitesi Rektoerluek Kuru öğütme yöntemi̇ i̇le hazirlanan ve çözünme hizi arttirilmiş selekoksi̇b i̇çeren farmasöti̇k kompozi̇syonlar
CN114306253B (zh) * 2021-11-16 2023-08-22 扬子江药业集团广州海瑞药业有限公司 格列美脲片剂及其制备方法
JP7745851B2 (ja) * 2021-12-24 2025-09-30 日本乳化剤株式会社 精製イオン液体の製造方法、セルロース溶解液および再生セルロース繊維の製造方法、ならびに繊維組成物および有機繊維コード
CN113996161B (zh) * 2021-12-30 2022-04-19 河北鑫鹏新材料科技有限公司 一种硫转移剂及其制备方法和应用
CN114732009B (zh) * 2022-06-13 2022-08-23 山东百农思达生物科技有限公司 一种含有吡唑醚菌酯和烯酰吗啉的水分散粒剂的制备方法
CN116196273B (zh) * 2023-03-31 2025-04-29 江苏慧聚药业股份有限公司 一种美洛昔康注射液及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2642486B2 (ja) * 1989-08-04 1997-08-20 田辺製薬株式会社 難溶性薬物の超微粒子化法
AU660852B2 (en) * 1992-11-25 1995-07-06 Elan Pharma International Limited Method of grinding pharmaceutical substances
JP4117811B2 (ja) * 1997-04-22 2008-07-16 日本化薬株式会社 フルタミド製剤及びその製法
SA99191255B1 (ar) * 1998-11-30 2006-11-25 جي دي سيرل اند كو مركبات سيليكوكسيب celecoxib
CN100457090C (zh) * 2000-08-31 2009-02-04 斯凯伊药品加拿大公司 磨制颗粒
JP2004099442A (ja) * 2002-09-04 2004-04-02 Nisshin Pharma Inc 難溶性薬物含有製剤およびその製造方法
CA2593862C (fr) * 2004-12-31 2014-10-21 Iceutica Pty Ltd Composition de nanoparticules et procedes de synthese de cette derniere
EP1973523A2 (fr) * 2005-12-15 2008-10-01 Acusphere, Inc. Fabrication de preparations pharmaceutiques a base de particules pour administration pulmonaire ou nasale
DE602006009710D1 (de) * 2005-12-15 2009-11-19 Acusphere Inc Verfahren zur herstellung von pharmazeutischen formulierungen auf teilchenbasis zur parenteralen verabreichung
NZ614995A (en) * 2006-06-30 2015-03-27 Iceutica Pty Ltd Methods for the preparation of biologically active compounds in nanoparticulate form
JP5508003B2 (ja) * 2006-06-30 2014-05-28 アイスイティカ ピーティーワイ リミテッド ナノ粒子状の形態における生物学的に活性な化合物の調製のための方法
BRPI1014275B8 (pt) * 2009-04-24 2021-05-25 Iceutica Pty Ltd composição que compreende partículas de indometacina dispersas em pelo menos dois materiais de moagem parcialmente moídos
CN106727424A (zh) * 2009-04-24 2017-05-31 伊休蒂卡有限公司 双氯芬酸的新剂型
AU2010239160B2 (en) * 2009-04-24 2014-10-02 Iceutica Pty Ltd Method for improving the dissolution profile of a biologically active material

Also Published As

Publication number Publication date
KR20150013948A (ko) 2015-02-05
JP5898613B2 (ja) 2016-04-06
IL215871B (en) 2019-07-31
AP3629A (en) 2016-03-08
CN102438600A (zh) 2012-05-02
US20180169018A1 (en) 2018-06-21
PH12015501781A1 (en) 2016-10-03
CN103830243A (zh) 2014-06-04
AP2015008965A0 (en) 2016-01-31
AP2011005994A0 (en) 2011-12-31
MX2011011217A (es) 2012-02-08
MY163538A (en) 2017-09-15
AU2010239160B2 (en) 2014-10-02
JP6619386B2 (ja) 2019-12-11
US20130277468A1 (en) 2013-10-24
KR101679522B1 (ko) 2016-11-24
IL215871A0 (en) 2012-01-31
BRPI1014277A2 (pt) 2016-10-18
WO2010121321A1 (fr) 2010-10-28
MX360545B (es) 2018-10-26
CN104825396A (zh) 2015-08-12
CO6470804A2 (es) 2012-06-29
AU2015243003A1 (en) 2017-05-04
CA2759104C (fr) 2019-01-29
JP2012524717A (ja) 2012-10-18
EP2421516A4 (fr) 2012-11-07
ZA201108647B (en) 2013-01-30
US20210401753A1 (en) 2021-12-30
CA2759104A1 (fr) 2010-10-28
KR101873500B1 (ko) 2018-08-02
EA201171280A1 (ru) 2012-09-28
US20200375903A1 (en) 2020-12-03
US20250049720A1 (en) 2025-02-13
JP2015199736A (ja) 2015-11-12
UA110772C2 (uk) 2016-02-25
SG175308A1 (en) 2011-11-28
EP2421516A1 (fr) 2012-02-29
NZ595972A (en) 2014-01-31
JP2017222643A (ja) 2017-12-21
KR20160098535A (ko) 2016-08-18
AU2010239160A1 (en) 2011-11-10
US20120165323A1 (en) 2012-06-28
KR20120047207A (ko) 2012-05-11

Similar Documents

Publication Publication Date Title
MA33293B1 (fr) Procédé d'amélioration du profil de dissolution d'une matière biologiquement active
BR112017008578A2 (pt) junta soldada a laser, componente de veículo, método de fabricação de junta soldada a laser e método de fabricação de componente de veículo
EP1928620A4 (fr) Procédé de granulation sous forme sphérique et d agglomération en particules métalliques et particules métalliques ainsi préparées, anodes fabriquées à partir des particules métalliques
BRPI0811364A2 (pt) "separador de aço inoxidável para uma célula de combustível e método para manufaturar o separador de aço inoxidável para célula de combustível"
CL2007003303A1 (es) Molecula de enlace para la proteina lingo-1; polinucleotido que la codifica; vector y celula que lo comprenden; composicion farmaceutica que comprende la molecula de enlace; y su uso para el tratamiento de lesiones del sistema nervioso central.
ZA200707353B (en) 4-cyclopropyl-1,2,3-thiadiazole compound, agrohorticultural plant disease controlling agent and method of using the same
EP2154204A4 (fr) Fines particules d'élastomère réticulé, contenant du fluor, leur procédé de fabrication, et composition
ATE296972T1 (de) Verfahren zur überwachung von lagern eines brechers und brecher
BRPI0716765A2 (pt) mÉtodos e composiÇÕes para administrar agentes hipoglicÊmicos de longa duraÇço
MA34670B1 (fr) Inhibiteurs de l'apoptose et leurs utilisations
EP2444483A3 (fr) Matériaux et procédés liés aux thérapies cellulaires
MX2009000418A (es) Composiciones en contra de la cocaina y tratamiento.
WO2006089114A3 (fr) Procedes et compositions pour le traitement d'un sujet souffrant d'un etat a mediation assuree par la toxine de l'anthrax
WO2007027559A3 (fr) Procedes et compositions de neuroprotection et de neurorestauration
WO2005121778A3 (fr) Procedes d'identification, et composes utiles pour le traitement de maladies degeneratives et inflammatoires
EP1849739A4 (fr) Monte-charge pour une utilisation dans un ascenseur et procede de remplacement de roulement pour ledit monte-charge
WO2006124862A3 (fr) Procedes pour le traitement d'etats pathologiques oculaires et de conditions neurodegeneratives chez un mammifere
IL194619A (en) The composition containing a surfactant and fluid for the visibility and impact of the surfactant
FR2911491B1 (fr) Ensemble implantable dans l'os de la machoire et installation pour la pose d'un tel ensemble.
MA37845B2 (fr) Compositions liquides orales pédiatriques contenant du nepadutant
EP1968651A4 (fr) Compositions stabilisées et procédés permettant de radiomarquer des produits pharmaceutiques avec des émetteurs de particules alpha
ITMI20051868A1 (it) Procedimento per saldare elementi da giuntare mediante un pezzo sagomato estruso di materiale di apporto di saldatura nonche' un tale pezzo sagomato da impiegare nella saldatura
WO2006094134A3 (fr) Anticorps kim-1 utilises dans le traitement des etats induits par th2
TW200738677A (en) Nitro-substituted hydroxyindoles, their use as inhibitors of phosphodiesterase 4, and processes for preparing them
Giles New Furnaces cut costs for oak ridge die caster